Differential Localization of Complement Component 3 within the Capsular Matrix ofCryptococcus neoformans
- 1 June 2006
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 74 (6), 3096-3106
- https://doi.org/10.1128/iai.01213-05
Abstract
The polysaccharide capsule of Cryptococcus neoformans is a powerful activator of the complement system. The goal of the present study was to assess serum and cellular variables that influence the sites for C3 binding within the capsular matrix. Confocal microscopy using fluorophore-labeled polyclonal anti-C3 and anticapsular monoclonal antibodies and rosetting of fluorescent microspheres coated with anti-C3 were used to identify sites of C3 binding relative to the capsular edge. The results showed that the source of serum was a major variable influencing localization of C3. C3 bound at or very near the capsular edge in the case of human serum. C3 deposition was further from the capsule edge with guinea pig and rat sera; in the case of mouse serum, there was no binding of C3 in the outer region of the capsule. Addition of human C3 to mouse serum led to deposition of the C3 at the capsular edge, indicating that distinct properties of mouse and human C3 account for the differential localization of C3. Finally, the density of the capsular matrix was an important variable in determining sites for C3 deposition. Yeast cells with a high concentration of polysaccharide near the capsule edge supported deposition of mouse C3 at or near the capsular edge, whereas cells with a low matrix density showed deposition well beneath the edge. Taken together, these results indicate that the spatial deposition of C3 within the capsular matrix is a complex process that is influenced by the serum source and the density of the capsular matrix.Keywords
This publication has 64 references indexed in Scilit:
- Molecular architecture of the Cryptococcus neoformans capsuleMolecular Microbiology, 2004
- The efficacy of complement‐mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirectC3‐mediated interactionsEuropean Journal of Immunology, 2003
- Contribution of Epitope Specificity to the Binding of Monoclonal Antibodies to the Capsule of Cryptococcus neoformans and the Soluble Form of Its Major Polysaccharide, GlucuronoxylomannanClinical and Vaccine Immunology, 2003
- Availability of Complement Bound toStaphylococcus aureusTo Interact with Membrane Complement Receptors Influences Efficiency of PhagocytosisInfection and Immunity, 2003
- The internal thioester and the covalent binding properties of the complement proteins C3 and C4Protein Science, 1997
- Phylogeny of the third component of complement, C3: Analysis of the conservation of human CR1, CR2, H, and B binding sites, concanavalin A binding sites, and thiolester bond in the C3 from different speciesDevelopmental & Comparative Immunology, 1992
- Complement Evasion by Bacteria and ParasitesAnnual Review of Microbiology, 1988
- Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide.Journal of Clinical Investigation, 1985
- The alternative pathway of complementSpringer Seminars in Immunopathology, 1984
- Third component of human complement: purification from plasma and physicochemical characterizationBiochemistry, 1976